Identification of targets and comparative study of administration methods for the lipid-lowering effects of fucoidan from Saccharina japonica

被引:0
|
作者
Chen, Pengwei [1 ]
Hao, Li [2 ]
Li, Quancai [3 ]
Wang, Hao [1 ]
Chen, Huiqin [1 ]
Zhang, Miao [4 ]
Jia, Ang [5 ]
Jiang, Hongfei [4 ]
Dai, Haofu [1 ]
Zhang, Renshuai [4 ]
机构
[1] Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Hainan Key Lab Res & Dev Nat Prod Li Folk Med, Haikou 571101, Peoples R China
[2] Shandong First Med Univ & Shandong Prov Qianfoshan, Affiliated Hosp 1, Dept Gerontol, Jinan 528051, Peoples R China
[3] Ocean Univ China, Marine Biomed Res Inst Qingdao, Qingdao 266003, Peoples R China
[4] Qingdao Univ, Affiliated Hosp, Qingdao 266071, Peoples R China
[5] Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou 121000, Peoples R China
关键词
Fucoidan; Lipid-lowering activity; Dietary supplementation; Intestinal target; Gut microbiota; NPC1L1; PROTEIN; CHOLESTEROL; ABSORPTION;
D O I
10.1016/j.ijbiomac.2024.139102
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lipid-lowering activity of fucoidan has been widely reported, but the exploration of its mechanisms is relatively limited, and studies on its direct targets are even scarcer. Additionally, it is unclear whether different administration methods affect the lipid-lowering activity of fucoidan. In current study, we used fucoidan derived from Saccharina japonica (SJF) to investigate its targets. The results showed that not only did SJF directly inhibit the Niemann-Pick C1-like 1 (NPC1L1)-mediated cholesterol transport, but it also reduced the solubility of cholesterol in mixed micelles, thereby interfering with the cholesterol uptake. Furthermore, SJF not only directly inhibited the activity of pancreatic triglyceride lipase (PTL), but also interfered with the overall catalytic process facilitated by colipase, thereby reducing the absorption of triglycerides. Moreover, comparative studies on the lipid-lowering activity of SJF administered via different methods demonstrated that dietary supplementation with SJF provided better lipid-lowering effects compared with gavage administration. Our research not only elucidates the targets and mechanisms of SJF but also provides theoretical basis for the selection of administration methods for fucoidan in lipid-lowering therapy.
引用
收藏
页数:9
相关论文
共 34 条
  • [21] Comparative study of the effect of different fucoidans from Sargassum maclurei and Saccharina japonica on FGFs/FGFR signaling activation in BaF3 cells
    Geng, Lihua
    Hou, Ningning
    Zhang, Meng
    Xu, Yingjie
    Zhang, Qi
    Wang, Jing
    Zhang, Lijuan
    Zhang, Quanbin
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 107 : 2429 - 2435
  • [22] Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization
    Zhang, Zhongxu
    Zhang, Daxin
    CANCER CAUSES & CONTROL, 2024, 35 (06) : 983 - 994
  • [23] Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine
    Wang, JX
    Lu, ZL
    Chi, JM
    Wang, WH
    Su, MZ
    Kou, WR
    Yu, PL
    Yu, LJ
    Zhu, JS
    Chang, J
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (12): : 964 - 978
  • [24] A dose-response study of the bioavailability of grape seed proanthocyanidin in rat and lipid-lowering effects of generated metabolites in HepG2 cells
    Margalef, Maria
    Guerrero, Ligia
    Pons, Zara
    Isabel Bravo, Francisca
    Arola, Lluis
    Muguerza, Begona
    Arola-Arnal, Anna
    FOOD RESEARCH INTERNATIONAL, 2014, 64 : 500 - 507
  • [25] Comparing in vitro digestion-fermentation characteristics and in vivo lipid-lowering effects of hot water and alkali-extracted polysaccharides from Volvariella volvacea
    Li, Shangyuan
    Bai, Juan
    Yuan, Jie
    Yang, Zihan
    Du, Qiulong
    Pan, Beibei
    Zhu, Ying
    Xiao, Xiang
    Li, Yu
    Li, Changtian
    JOURNAL OF FOOD SCIENCE, 2025, 90 (04)
  • [26] Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II
    Gitt, Anselm K.
    Lautsch, Dominik
    Ferrieres, Jean
    De Ferrari, Gaetano M.
    Vyas, Ami
    Baxter, Carl A.
    Bash, Lori D.
    Ashton, Veronica
    Horack, Martin
    Almahmeed, Wael
    Chiang, Fu-Tien
    Poh, Kian Keong
    Brudi, Philippe
    Ambegaonkar, Baishali
    ATHEROSCLEROSIS, 2017, 266 : 158 - 166
  • [27] Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS)
    Ferrieres, Jean
    Lautsch, Dominik
    Gitt, Anselm K.
    De Ferrari, Gaetano
    Toplak, Hermann
    Elisaf, Moses
    Drexel, Heinz
    Horack, Martin
    Baxter, Carl
    Ambegaonkar, Baishali
    Brudi, Philippe
    Toth, Peter P.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11) : 2670 - 2674
  • [28] Effects of sulfated fucan, ascophyllan, from the brown Alga Ascophyllum nodosum on various cell lines: A comparative study on ascophyllan and fucoidan
    Jiang, Zedong
    Okimura, Takasi
    Yokose, Takeshi
    Yamasaki, Yasuhiro
    Yamaguchi, Kenichi
    Oda, Tatsuya
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 2010, 110 (01) : 113 - 117
  • [29] Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie SocietA Italiana di Medicina Interna) Study
    Bertolotti, Marco
    Franchi, Carlotta
    Rocchi, Marco B. L.
    Miceli, Andrea
    Libbra, M. Vittoria
    Nobili, Alessandro
    Lancellotti, Giulia
    Carulli, Lucia
    Mussi, Chiara
    DRUGS & AGING, 2017, 34 (04) : 311 - 319
  • [30] Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register
    Hero, Christel
    Karlsson, Sofia Axia
    Franzen, Stefan
    Svensson, Ann-Marie
    Miftaraj, Mervete
    Gudbjornsdottir, Soffia
    Andersson Sundell, Karolina
    Eliasson, Bjorn
    Eeg-Olofsson, Katarina
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)